163215-99-4

Upstream product

• 18951-85-4 (R)-citronellic acid 
• 163215-96-1 (R)-3,7-Dimethyl-oct-6-enoic acid (R)-3-methyl-cyclohex-2-enyl ester 
• 163215-98-3 (2R,3R)-3,7-dimethyl-2((1S)-1-methyl-2-cyclohexenyl)-6-octen-1-ol 
• 248915-99-3 (2R,3R)-3,7-dimethyl-2((1S)-1-methyl-2-cyclohexenyl)-6-octen-1-ol tosylate 

Downstream Products

• 248916-00-9 (S)-3-Methyl-3-((1R,2R)-1,2,6-trimethyl-6-triethylsilanyloxy-heptyl)-cyclohexanol 
• 181116-72-3 (1S,5R)-1,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-3-[2-[(S)-3-methyl-3-((1R,2R)-1,2,6-trimethyl-6-triethylsilanyloxy-heptyl)-cyclohex-(E)-ylidene]-eth-(Z)-ylidene]-cyclohexane 
• 163216-00-0 (6R,7R)-2,6,7-trimethyl-7-((1S)-1-methyl-2-cyclohexenyl)-heptan-2-ol 

Relevant academic research and scientific papers

Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1α,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20

The synthesis of four CD-ring-modified 19-nor-1α,25-dihydroxyvitamin D3 derivatives lacking C15, referred to as 6C analogues, and diastereomeric at C17 and C20 is described. The synthesis involves an Ireland-Claisen rearrangement of a 3-methyl-